Orthocell Hits US Milestone - 100 Remplir Units Sold.
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Orthocell's CEO expressed confidence in the company's growth trajectory, noting that early surgical adoption has exceeded expectations and is expected to continue as hospital approvals progress. The filing highlights the company's strong financial position, with substantial cash reserves and no debt, supporting ongoing investments in market adoption and clinical evidence.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Orthocell
- Remplir Regulatory Application for US$750m EU-UK Market
- First Commercial Sales of Remplir Achieved in Hong Kong
- Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Surgeons Nationwide
- Remplir gains momentum in nerve-sparing prostate surgery
- 2nd Distributor in Canada, Entire $75m Market Now Covered
Later from Orthocell
- Orthocell Posts Seventh Straight Record Revenue Quarter
- Quarterly Activity Report & Appendix 4C
- US Market and Operational Update
- Orthocell Receives $3.0m R&D Tax Refund
- Appendix 4D & Half-Year Financial Report
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell